The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia

American Journal of Clinical Pathology

Volumn 130, Issue 3, 2008, Pages 336-342

  Gianelli, Umberto ^a   Iurlo, Alessandra ^b   Vener, Claudia ^a   Moro, Alessia ^a   Fermo, Elisa ^b   Bianchi, Paola ^b   Graziani, Daniela ^a   Radaelli, Franca ^b   Coggi, Guido ^a   Bosari, Silvano ^a   Deliliers, Giorgio Lambertenghi ^a   Zanella, Alberto ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS   (Italy)

Author keywords

Bone marrow biopsy; Differential diagnosis; Early prepolycythemic polycythemia vera; Essential thrombocythemia; JAK2V617F mutation; Polycythemia vera

Indexed keywords

JANUS KINASE 2; PHENYLALANINE; VALINE;

ADULT; AGED; ALGORITHM; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CLINICAL ARTICLE; CLINICAL FEATURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ERYTHROPOIESIS; FEMALE; GENE MUTATION; GRANULOPOIESIS; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPLASIA; MALE; MEGAKARYOCYTE; PARAMETER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTHEMIA;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BONE MARROW; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; RETROSPECTIVE STUDIES; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 51349150784     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/6BQ5K8LHVYAKUAF4     Document Type: Article

References (30)

1. Pierre R, Imbert M, Thiele J, et al. Polycythemia vera. In: Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:32-34. World Health Organization Classification of Tumours.
2. Bilgrami S, Greenberg BR. Polycythemia rubra vera. Semin Oncol. 1995;22:307-326.
3. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100:4272-4290.
4. Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythaemia vera with thrombocytosis mimicking essential thrombocythaemia. Acta Haematol. 2005;113:213-219.
5. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol. 1999;36:9-13.
6. Jantunen R, Juvonen E, Ikkala E, et al. Development of erythrocytosis in the course of essential thrombocythemia. Ann Hematol. 1999;78:219-222.
7. Shih LY, Lee CT. Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood. 1994;83:744-748.
8. Thiele J, Kvasnicka HM. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol. 2005;20:317-328.
9. Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica. 2004;89:1194-1198.
10. Reid CD. The significance of endogenous erythroid colonies (EEC) in haematological disorders. Blood Rev. 1987;1:133-140.
11. Temerinac S, Klippel S, Strunck E, et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood. 2000;95:2569-2576.
12. Liu E, Jelinek J, Pastore YD, et al. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assay and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 2003;101:3294-3301.
13. Boch O, Serinsoz E, Neusch M, et al. The polycythaemia rubra vera-1 gene is constitutively expressed by bone marrow cells and does not discriminate polycythaemia vera from reactive and other chronic myeloproliferative disorders. Br J Haematol. 2003;123:472-474.
14. Sirhan S, Lasho TL, Elliott MA, et al. Neutrophil polycythemia rubra vera-1 expression in classic and atypical myeloproliferative disorders and laboratory correlates. Haematologica. 2005;90:406-408.
15. Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia. 2005;19:1847-1849.
16. McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2V617F mutation in chronic myeloproliferative disorders. Leukemia. 2006;20:168-171.
17. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
18. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162-2168.
19. Levine RL, Belisle C, Wadleigh M, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood. 2006;107:4139-4141.
20. Scott LM, Campbell PJ, Baxter EJ, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood. 2005;106:2920-2921.
21. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452-2466.
22. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
23. Florena AM, Tripodo C, Iannitto E, et al. Value of bone marrow biopsy in the diagnosis of essential thrombocythaemia. Haematologica. 2004;89:911-919.
24. Gianelli U, Vener C, Raviele PR, et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma. 2006;47:1774-1781.
25. Kaplow LS. Cytochemistry of leukocyte alkaline phosphatase: use of complex naphthol as phosphates in azo dyecoupling technics. Am J Clin Pathol. 1963;39:439-449.
26. Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood. 2006;108:3548-3555.
27. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459-468.
28. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092-1097.
29. Kvasnicka HM, Thiele J. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost. 2006;32:362-371.
30. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755-761.